CMX001

Phase 2Withdrawn

0 views this week 0 watching💤 Quiet

Interest: 24/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Ebola Virus

Conditions

Ebola Virus

Trial Timeline

Oct 1, 2014 → Jan 1, 2015

NCT ID

NCT02271347

About CMX001

CMX001 is a phase 2 stage product being developed by Jazz Pharmaceuticals for Ebola Virus. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT02271347. Target conditions include Ebola Virus.

What happened to similar drugs?

2 of 4 similar drugs in Ebola Virus were approved

Approved (2) Terminated (1) Active (1)

✅rVSVDG-ZEBOV-GP Ebola Virus Vaccine (ERVEBO)MerckApproved

🔄V920 Consistency Lot A + V920 Consistency Lot B + V920 Consistency Lot C + V920 High-dose Lot + Placebo to V920MerckPhase 3

✅BioNTech - Pfizer COVID-19 vaccine + 1mL saline solution + rVSV∆G-ZEBOV-GPMerckApproved

❌Ad26.ZEBOV + MVA-BN-FiloBavarian NordicPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02271347	Phase 2	Withdrawn	Oct 1, 2014	Jan 1, 2015	Ebola Virus
NCT02167685	Pre-clinical	Terminated	Jan 1, 2014	May 10, 2019	Outcomes
NCT05391724	Phase 1	Completed	Feb 1, 2011	Sep 1, 2011	Hepatic Impairment
NCT00780182	Phase 1	Completed	Oct 1, 2008	Jan 1, 2009	Healthy

Competing Products

20 competing products in Ebola Virus

See all competitors

Product	Company	Stage	Hype Score
Ad26.ZEBOV vaccine	Johnson & Johnson	Phase 2	35
rVSVΔG-ZEBOV-GP, V920 + Chikenpox or Varicella vaccine (VARILRIX)	Merck	Phase 1/2	32
V920 Vaccine	Merck	Phase 1	29
Recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP)	Merck	Phase 2	39
rVSVDG-ZEBOV-GP Ebola Virus Vaccine (ERVEBO)	Merck	Approved	50
V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine	Merck	Phase 2	35
V920	Merck	Phase 1	29
V920 Consistency Lot A + V920 Consistency Lot B + V920 Consistency Lot C + V920 High-dose Lot + Placebo to V920	Merck	Phase 3	40
BioNTech - Pfizer COVID-19 vaccine + 1mL saline solution + rVSV∆G-ZEBOV-GP	Merck	Approved	50
V920	Merck	Phase 1	29
GS-5734	Gilead Sciences	Phase 2	35
REGN3470-3471-3479	Regeneron Pharmaceuticals	Pre-clinical	30
Ervebo + Inmazeb	Regeneron Pharmaceuticals	Phase 2	42
AVI-7537	United Therapeutics	Phase 1	18
Placebo + AVI-6002	United Therapeutics	Phase 1	26
Ad26.ZEBOV + MVA-BN-Filo	Bavarian Nordic	Phase 3	29
Brincidofovir	Jazz Pharmaceuticals	Phase 2	24
cAd3-Marburg + cAd3-EBO-S	ICON plc.	Phase 1	26
Base Dose EBOV GP Vaccine + 2x Base Dose EBOV GP Vaccine + 4x Base Dose EBOV GP Vaccine + 8x Base Dose EBOV GP Vaccine + Placebo + Matrix-M Adjuvant	Novavax	Phase 1	23
TKM-100802 for Injection + Placebo	Arbutus Biopharma	Phase 1	15